amg-208
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2008 (NCT00813384)
Timeline
Indications
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1- Mol. weight
- 383.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL496102 ↗
Also known as
- 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline
- 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline
- amg 208
- amg 208
- amg-208
- amg-208
- amg-208
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02420587 | Phase 2 | Oct 1, 2014 | Amgen, University of Texas at Houston |
| NCT00813384 | Phase 1 | Dec 1, 2008 | Amgen |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 2 | 1 | 2 | 2008 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2014 |
2 organizations
Page 1 / 1